

ACURA PHARMACEUTICALS, INC

Form 8-K

September 15, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act Of 1934

September 15, 2014

Date of Report (Date of earliest event reported)

ACURA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

State of New York

1-10113

11-0853640

(State of Other Jurisdiction (Commission File Number) (I.R.S. Employer

of Incorporation)

Identification Number)

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K

616 N. North Court, Suite 120

Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

(847) 705-7709

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-J(b))

- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-L(c))

Item 8.01 Other Events

On September 15, 2014 we issued a press release regarding our submission of a formal dispute resolution request with the US Food and Drug Administration (FDA) regarding Vycavert®, our AVERSION® hydrocodone with acetaminophen tablet development candidate. The dispute pertains to the FDA's determination that nasal snorting abuse of hydrocodone with acetaminophen products lacks relevance, thus making Vycavert® ineligible for abuse-deterrent labeling regardless of its abuse-deterrent profile.

The press release is attached hereto and filed as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

Exhibit Number Description

99.1 Press Release dated September 15, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACURA PHARMACEUTICALS, INC.

By: /s/ Peter A. Clemens
Peter A. Clemens
Senior Vice President & Chief Financial Officer

Date: September 15, 2014

Exhibit Index

Exhibit Number Description

99.1	Press Release dated September 15, 2014
------	--